The Board of Directors, in agreement with Marie Meynadier, CEO of EOS imaging, has decided to change the leadership of the company to strengthen its presence in the United States, its largest market, and expand its shareholder base.
The board has unanimously appointed Mike Lobinsky, who joined the company in August 2017 as president North America, to CEO. Meynadier will continue as CEO of EOS Imaging until Dec. 31, and thereafter will retain a position on the Board of Directors. Also being considered is Lobinsky’s nomination to director of EOS imaging at a subsequent shareholder general meeting.
Meynadier said, "I have enjoyed working with Mike for over a year. His leadership and knowledge of the industry, combined with his fine understanding of corporate culture, are excellent assets for EOS imaging and I have complete confidence in his ability to continue and accelerate the development of the company. Our North American market is considerable, and Mike will be able to develop it without denying our European roots, relying on the talented management team present in Paris, particularly Eric Maulavé, chief operating officer, to continue to drive global growth. It was an honor and a great pleasure to serve the company and to develop it since its foundation. I am most grateful to the men and women within our staff, to our directors, shareholders and clinical partners, who contributed to this development over these last years. Our teams can be proud of the work accomplished, and I have full confidence that they will continue to build our success under Mike’s leadership."
Lobinsky has over 20 years of experience in the medtech industry with senior management roles in sales, marketing, operations and business development in the fields of orthopedic robotics, navigation, imaging, and implants. He has held leadership positions at Smith and Nephew, Brainlab, Blue Belt Technologies, Stryker Corp., and most recently contributed to the acquisition of Blue Belt by Smith and Nephew prior to joining EOS in 2018.
Board Chairman Gérard Hascoet commented: "Marie's vision, her energy and her remarkable managerial talent have brought EOS imaging to a stage of excellence and a unique international reputation. Marie has given the company access today to an acceleration opportunity in the United States, which is a new step. She has managed to attract a management team capable of taking up this new challenge and ensure a successful succession. It is rare to be able to apprehend the future in such optimism."
"I am very grateful to Marie and the board members for their trust and pleased to accept the CEO position," Lobinsky said. "Few companies have accomplished what EOS has and these achievements have established a strong foundation for further development. The potential of our entire solution is outstanding, and I am confident in our ability to translate this into growth and value in the short, medium, and long terms."
Valérie Worrall also joins the company as Chief Financial Officer. Valérie Worrall has more than 20 years of experience in leadership finance roles and as the chief financial officer (CFO) within business units in the healthcare industry. She has held positions in South East Asia, the United States, Switzerland, the United Kingdom, and France. She most recently was CFO of Balt, a medical device company.
EOS imaging designs, develops, and markets EOS, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics, combining equipment and services and targeting a $2 billion per year market opportunity. EOS imaging is currently present in 33 countries, including the United States under U.S. Food and Drug Administration agreement, Japan, China and the European Union under CE labelling, through the more than 280 installed EOS platforms representing over 1 million patient exams every year. Revenues were 37.1 million euros in 2017, e.g. a more than 32 percent CAGR over 2012-2017.